IN8bio Faces Delisting Concerns, Shareholder Nominations Filed
Ticker: INAB · Form: 8-K · Filed: Feb 7, 2025 · CIK: 1740279
| Field | Detail |
|---|---|
| Company | In8bio, Inc. (INAB) |
| Form Type | 8-K |
| Filed Date | Feb 7, 2025 |
| Risk Level | high |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $1.00 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, shareholder-nomination
TL;DR
IN8BIO might get delisted, and shareholders are nominating people. Big trouble.
AI Summary
IN8bio, Inc. filed an 8-K on February 7, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company also reported shareholder nominations pursuant to Exchange Act Rule 14a-11. The filing date indicates the earliest event reported was February 5, 2025.
Why It Matters
This filing signals potential financial distress or non-compliance with listing standards, which could lead to the company's stock being delisted from its exchange, impacting liquidity and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards is a significant red flag indicating potential severe financial or operational issues.
Key Players & Entities
- IN8BIO, INC. (company) — Registrant
- February 5, 2025 (date) — Date of earliest event reported
- February 7, 2025 (date) — Filing date
- Exchange Act Rule 14a-11 (legal_document) — Shareholder nominations
FAQ
What specific listing rule has IN8bio, Inc. failed to satisfy?
The filing does not specify the exact listing rule that IN8bio, Inc. has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule has been issued.
What is the significance of the shareholder nominations filed under Exchange Act Rule 14a-11?
Shareholder nominations under Rule 14a-11 typically relate to the election of directors, suggesting potential changes in the company's board composition or a proxy contest.
What is the primary reason for this 8-K filing?
The primary reasons for this 8-K filing are to report a notice of delisting or failure to satisfy a continued listing rule and to report shareholder nominations pursuant to Exchange Act Rule 14a-11.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on February 5, 2025.
What is the former name of IN8bio, Inc. and when did the name change occur?
The former name of IN8bio, Inc. was Incysus Therapeutics, Inc., and the name change occurred on May 10, 2018.
Filing Stats: 1,094 words · 4 min read · ~4 pages · Grade level 14.3 · Accepted 2025-02-07 16:02:10
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share INAB The Nasdaq
- $1.00 — the Company's common stock is at least $1.00 per share for a minimum of 10 consecuti
Filing Documents
- d841361d8k.htm (8-K) — 29KB
- 0001193125-25-022711.txt ( ) — 152KB
- inab-20250205.xsd (EX-101.SCH) — 3KB
- inab-20250205_lab.xml (EX-101.LAB) — 18KB
- inab-20250205_pre.xml (EX-101.PRE) — 11KB
- d841361d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IN8bio, Inc. Dated: February 7, 2025 By: /s/ Patrick McCall Patrick McCall Chief Financial Officer and Secretary (Principal Financial and Accounting Officer)